Compare Edwards Lifesciences Corporation Common Stock (EW) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Edwards Lifesciences Corporation Common Stock vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? Edwards Lifesciences Corporation Common Stock trades at $84.25 (market cap $49.44B), while iShares 20 Plus Year Treasury Bond ETF trades at $77.8 (market cap $47.56B). The key difference: Edwards Lifesciences Corporation Common Stock and iShares 20 Plus Year Treasury Bond ETF are close in size by market cap, and Edwards Lifesciences Corporation Common Stock is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| EW | TLT | |
|---|---|---|
Market Cap | $49.44B | $47.56B |
Volume | 3,508,027 | 39,684,163 |
Sector | Health | Fixed Income |
52-Week High | $95.18 | $92.06 |
52-Week Low | $72.65 | $77.11 |
Enterprise Value | $45.90B | — |
Typical Hold Time | — | 83 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TLT, the iShares 20+ Year Treasury Bond ETF, trades at $77.145, down 0.17% on the day and near multi-year lows amid a prolonged bond market selloff. Technical indicators are bearish, with moving averages signaling strong selling pressure, while oversold RSI readings suggest potential for a near-term bounce. The fund continues to pay dividends, with recent payments of $0.31-$0.33 per share, but key financial ratios are unavailable as it is an ETF tracking long-term Treasury bonds.
The outlook for TLT remains heavily tied to the direction of long-term interest rates. Rising yields have pressured prices, but current levels may attract income-focused investors seeking high yields. Key risks include further Fed tightening, persistent inflation, and economic growth surprises that could extend the bond bear market. Analyst sentiment is cautious given the unfavorable rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Edwards Lifesciences Corporation Common Stock
Edwards Lifesciences develops medical technologies for structural heart disease. Its products include transcatheter aortic-valve replacement, mitral and tricuspid therapies, and surgical structural-heart technologies.
Read more on EW →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
